ArticleCureus2026
Predicting the Course of Immunoglobulin A Nephropathy Using Urinary Soluble Cluster of Differentiation 163 as a Prognostic Biomarker.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin A nephropathy (IgAN) is the most prevalent primary glomerulonephritis (GN) worldwide and is often underdiagnosed because of its asymptomatic presentation. Proteinuria-based assessment in monitoring disease progression is limited. Early renal biopsy may fail to predict disease severity. So, the development of a non-invasive biomarker can predict early disease progression.
objectiveTo evaluate urinary soluble cluster differentiation 163 (u-sCD163) in predicting short-term treatment response and its correlation with histologic activity in biopsy-proven IgAN. METHODOLOGY: This prospective observational study was carried out at the Department of Nephrology, Bangladesh Medical University (BMU), Dhaka, Bangladesh. A total of 55 patients with biopsy-proven primary IgAN were enrolled. Urine routine microscopic examination (R/M/E), 24-hour urinary total protein (UTP), and serum creatinine were measured at baseline, and at each follow-up (every three-month interval, up to six months). u-sCD163 was measured at baseline and at the sixth month. Patients were managed according to the KDIGO, 2021guideline and followed up in the third and sixthmonths.
resultsMean age of the study patients was 31.3 ± 5.61 years. The sex distribution highlights a male predominance, as the male-to-female ratio was 1.7:1. Baseline u-sCD163 was 3.78 ± 0.96 ng/mg in the partial response group and 7.82 ± 4.00 ng/mg in the no-response group (
conclusionsu-sCD163 may be a potential biomarker to predict the short-term treatment response status and histologic activity in biopsy-proven IgAN. Elevated biomarkers at baseline were associated with more proteinuria and risk of response failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.